No­var­tis qui­et­ly hands top­i­cal treat­ment for rare dis­ease to Life­Max — lat­est in a string of out-li­cens­ing deals

The steady stream of out­ward deals flow­ing from No­var­tis made a rare dis­ease turn to­day.

Pa­lo Al­to-based Life­Max Lab­o­ra­to­ries has li­censed BPR277, a clin­i­cal stage oint­ment that treats a rare con­di­tion af­fect­ing the skin, hair and im­mune sys­tems called Nether­ton syn­drome. Caused by mu­ta­tions in the SPINK5 gene, the dis­ease can be life-threat­en­ing for new­borns. Cur­rent treat­ments con­sist of var­i­ous top­i­cal re­lief prod­ucts and an­tibi­otics with no FDA-ap­proved prod­ucts tar­get­ing the dis­ease it­self.

Lar­ry Hsu

That’s ex­act­ly the type of dis­eases Life­Max is go­ing af­ter — those with few or no ther­a­peu­tic op­tions. In fact, its lead prod­uct, LM-030, is a top­i­cal treat­ment for the very con­di­tion. The com­pa­ny’s pipeline in­di­cates that the as­set is ap­proach­ing Phase III.

As in the re­cent deals with Chi­nese biotechs Laek­na and Ad­lai Nortye where No­var­tis cast off sev­er­al can­cer drugs, the terms were not dis­closed.

No­var­tis had, from 2011 to 2014, run a two-part study first eval­u­at­ing BRP277 safe­ty then its ef­fi­ca­cy in treat­ing atopic der­mati­tis and Nether­ton syn­drome, though the re­sults could not be found on clin­i­cal­tri­

In their an­nounce­ment of the deal, Life­Max wrote the ther­a­py comes with “pos­i­tive clin­i­cal proof of con­cept.” We reached out to clar­i­fy how they might ad­just their strat­e­gy based on the new as­set; we will up­date the sto­ry when we hear back.

“We are very ex­cit­ed to en­ter in­to this li­cens­ing agree­ment with No­var­tis and are com­mit­ted to con­tin­u­ing the de­vel­op­ment of BPR277 which fits well with our cor­po­rate strat­e­gy of de­vel­op­ing drugs for dis­eases with few or no ther­a­peu­tic op­tions,” said Lar­ry Hsu, Life­Max’s Co-founder and CEO. “This re­la­tion­ship is a tes­ta­ment to our drug de­vel­op­ment ca­pa­bil­i­ty and ex­per­tise. We look for­ward to bring­ing this much need­ed ther­a­py to peo­ple with Nether­ton Syn­drome, and po­ten­tial­ly oth­er dis­eases with skin bar­ri­er im­pair­ment.”

This is Hsu’s sec­ond spring as an en­tre­pre­neur. He had pre­vi­ous­ly found­ed and run Im­pax Phar­ma­ceu­ti­cals, which even­tu­al­ly be­came part of the gener­ics and spe­cial­ty phar­ma com­pa­ny Am­neal.

Post-re­tire­ment from Im­pax, Hsu al­so found­ed two ven­ture funds in­clud­ing Her­cules Bio-Ven­ture Part­ners, where he is still gen­er­al part­ner.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

FDA de­ci­sion on Ver­tex's CF triple will come just ahead of planned CEO shake­up

Vertex has clinched a priority review for the all-important cystic fibrosis triple that will blaze the trail for treating a large group of patients unhelped by its current drugs.

FDA regulators have set a PDUFA date of March 19, 2020, just a year after the Boston biotech posted positive Phase III results showing that people with two F508del mutations experienced statistically significant improvements in lung function after a 4-week regimen of VX-445, tezacaftor and ivacaftor. After reviewing 24-week data among patients with one F508del mutation and one minimal function mutation — and thoroughly comparing the VX-445 triple with another combo featuring VX-659 on scores like safety, drug-drug interactions, and photosensitivity — Vertex ultimately went with VX-445.

An MIT spin­out kills one of its ‘liv­ing ther­a­peu­tics’ af­ter flunk­ing an ear­ly-stage study — shares rout­ed

Just a few weeks after bagging $80 million in a deal to collaborate with Gingko Bioworks on its special blend of engineered bacteria used for “living therapeutics,” little Synlogic in Boston $SYBX is tossing one of its two clinical programs after watching an early-stage study go down in defeat.

Their Phase Ib/IIa study for SYNB1020 to counter the accumulation of ammonia in the body, a condition called hyperammonemia or urea cycle disorder, floundered at the interim readout, forcing the biotech to kill it and reserve its cash for pipeline therapies with greater potential.

Elan­co to buy Bay­er's an­i­mal health busi­ness for $7.6B, as deal­mak­ing gath­ers steam in the sec­tor

Last week, Elanco explicitly dodged answering questions about its rumored interest in Bayer’s animal health business in its post-earnings call. On Tuesday, the Eli Lilly spinoff disclosed it was purchasing the German drug maker’s veterinary unit in a cash-and-stock deal worth $7.6 billion. 

Elanco $ELAN has been busy on the deal-making front. In April, it laid out plans to swallow its partner, Kansas-based pet therapeutics company Aratana $PETX. A July report by Reuters suggested a potential Bayer deal was being explored, and Bloomberg last week said the deal was imminent, citing sources. 

As­traZeneca's di­a­betes drug Farx­i­ga helps pa­tients with heart dis­ease and with­out di­a­betes in land­mark tri­al

Months ago, data on J&J’s $JNJ Invokana indicated the diabetes drug conferred cardiovascular (CV) benefit in patients who do and do not have preexisting CV disease. On Tuesday, AstraZeneca’s $AZN rival treatment, Farxiga, was shown to cut the risk of CV death or the worsening of heart failure in patients with heart disease, in a landmark trial.

The treatments, in addition to Jardiance from Eli Lilly $LLY, belong to a class of diabetes drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by curbing the absorption of glucose via the kidneys so that surplus glucose is excreted through urination.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.